Syn-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate)

Identity matters

Syn-AKE is not simply a conventional tripeptide. The beta-alanine, proline, diaminobutyric-acid benzylamide core and two acetate counterions define the supplied chemical form. Reporting only “Tripeptide-3” can confuse it with AHK and other unrelated cosmetic sequences, so analytical records should use the INCI name, CAS and salt state.

Waglerin-inspired design

Waglerin-1 is a substantially larger venom peptide with subtype-selective nicotinic receptor pharmacology. Syn-AKE was developed as a compact structural mimic for cosmetic research, but similarity of design intent does not establish equivalent receptor selectivity. Direct receptor, contraction and cytotoxicity measurements are required in each model.

Suggested comparison design

• Waglerin-1 reference where institutional controls permit
• Vialox for a different postsynaptic antagonist hypothesis
• Argireline or SNAP-8 for SNARE-related presynaptic comparisons
• Cell viability and membrane-integrity readouts alongside contraction frequency

Quantifying the supplied form

A reduced contraction readout can reflect receptor antagonism, nonspecific toxicity or assay interference. The compound's INCI use does not prove that raw concentrated material is suitable for people, and hazard classifications may vary by supplier and salt form. Work should remain inside an approved laboratory chemical-hygiene process with appropriate exposure controls.

Handle the powder as a concentrated research chemical using the laboratory's risk assessment and personal-protective-equipment requirements. Let the sealed vial equilibrate before opening, prepare stock with water or validated neutral buffer and mix gently. Document that calculations use the 495.57 g/mol diacetate form rather than the unsalted parent. Store dry at −20 °C, protected from moisture and light; refrigerate defined short-term stocks and avoid repeated freeze–thaw cycles.